We are live on ! Find out more
OCUL icon

Ocular Therapeutix

68 hedge funds and large institutions have $88.6M invested in Ocular Therapeutix in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 25 increasing their positions, 20 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

291% more call options, than puts

Call options by funds: $751K | Put options by funds: $192K

25% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 20

22% more capital inflows, than outflows

Capital inflows: $14.6M | Capital outflows: $11.9M

0% more funds holding

Funds holding: 68 → 68 (0)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.42% less ownership

Funds ownership: 52.53% → 52.11% (-0.42%)

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

Holders
68
Holders Change
–
Holders Change %
0%
% of All Funds
1.47%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
8
Increased
25
Reduced
20
Closed
9
Calls
$751​K
Puts
$192​K
Net Calls
+$559​K
Net Calls Change
+$410​K

OCUL Hedge Fund Activity: Q1 2019 in Review

68 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2019, worth a combined $88.6M — up 2.6% from $86.4M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of OCUL and 8 opened new positions — a net loss of 1 holder — while 20 trimmed existing stakes and 25 added.

The largest buyer was Opaleye Management, opening a new position worth an estimated $7.64M. The largest seller was Jennison Associates, cutting an estimated $5.55M.

  • 68 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2019, unchanged from Q4 2018.
  • Funds reported $88.6M of Ocular Therapeutix stock for Q1 2019, up 2.6% quarter-over-quarter.
  • 8 funds opened new Ocular Therapeutix positions in Q1 2019 and 9 closed out, a net change of -1 holder.
  • The largest Ocular Therapeutix buyer in Q1 2019 was Opaleye Management, an estimated $7.64M added.
  • The largest Ocular Therapeutix seller in Q1 2019 was Jennison Associates, an estimated $5.55M sold.

Based on aggregated 13F filings for Q1 2019.